Skip to main navigation
Skip to Content
logo
  • About
  • Overview
  • News & Events
    • News Releases
    • Events & Presentations
  • Financial Reports
    • Annual Reports
    • Quarterly & Other Reports
    • SEC Filings
  • Stock Info
    • Stock Quote and Chart
    • Historic Stock Lookup
    • Investment Calculator
  • Analyst Coverage
  • Corporate Governance
    • Documents and Charters
    • Our Team
    • Committee Composition
  • Investor Resources
    • Email Alerts
    • Contact Us

News Releases

News Releases

Keyword Search

Jun-01-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May-26-2022
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
May-05-2022
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
May-02-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Apr-28-2022
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
Apr-13-2022
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
Apr-01-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mar-10-2022
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
Mar-07-2022
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results
Mar-01-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
Print
RSS Feeds
Email Alerts
Contact IR
Search
  • © 2023 Oncternal Therapeutics, Inc. All rights reserved.